jcm-logo

Journal Browser

Journal Browser

Treatment of Bladder Cancer: From Past to Future

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Oncology".

Deadline for manuscript submissions: 25 September 2025 | Viewed by 3069

Special Issue Editor


E-Mail Website
Guest Editor
Department of Urology, Arhus University Hospital, 8200 Aarhus, Denmark
Interests: urology; bladder cancer; nonmuscle invasive bladder cancer; muscle-invasive bladder cancer

Special Issue Information

Dear Colleagues,

Bladder cancer is a frequent cancer type with a high degree of diversity regarding its prognosis and treatment modalities. The incidence of bladder cancer has been almost unaltered over the past decades despite the focus on smoking and work enviromental improvements. Thus, the reduction in these factors has been upweighted by an increasing life expectancy in the Western World. During the last decade, previous stagnation in the development of new treatment modalities has changed into an explosion of new local and systemic treatments. Immuotherapy showed promising results when introduced, but the initial enthusiasm was quickly changed to a more realistic expectation of a game changer in just a minority of patients; however, this fact has paved the way for more individualized tailor-made treametments. We are on the verge of a new future for bladder cancer treatments. With this Special Issue, we hope to focus on an up-to-date mapping of the current status of bladder cancer and highlight new promising fields of diagnostics, treatments, and follow-ups.

Prof. Dr. Jørgen Bjerggaard Jensen
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • urology
  • bladder cancer
  • urothelial cancer
  • nonmuscle-invasive bladder cancer
  • muscle-invasive bladder cancer

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Other

12 pages, 2161 KiB  
Article
[15O]H2O PET/MRI for Assessment of Complete Response to Neoadjuvant or Induction Chemotherapy in Patients with Muscle-Invasive Bladder Cancer: A Pilot Study
by Stefanie Korsgaard Körner, Lars Poulsen Tolbod, Bodil G. Pedersen, Thierry Boellaard, Rikke Vilsbøll Milling, Simone Buchardt Brandt, Mads Agerbæk, Lars Dyrskjøt, Kirsten Bouchelouche and Jørgen B. Jensen
J. Clin. Med. 2024, 13(16), 4652; https://doi.org/10.3390/jcm13164652 - 8 Aug 2024
Viewed by 1239
Abstract
Background: Accurate assessment of therapy response to chemotherapy could possibly offer a bladder-sparing approach in selected patients with localized muscle-invasive bladder cancer (MIBC). The aim of this study was to evaluate whether [15O]H2O PET/MRI can be used for assessment [...] Read more.
Background: Accurate assessment of therapy response to chemotherapy could possibly offer a bladder-sparing approach in selected patients with localized muscle-invasive bladder cancer (MIBC). The aim of this study was to evaluate whether [15O]H2O PET/MRI can be used for assessment of complete local pathological response to preoperative chemotherapy in patients with MIBC. Methods: This prospective pilot study included 13 patients with MIBC treated with neoadjuvant or induction chemotherapy and subsequent radical cystectomy. Patients underwent a [15O]H2O PET/MRI scan before chemotherapy and another scan after chemotherapy before radical cystectomy. Volumes of interest were delineated on T2-weighted MRI and transferred to parametric images for dynamic analysis. Tumor blood flow (TBF) was estimated by [15O]H2O PET. Changes in TBF were compared with histopathology. The Wilcoxon matched-pairs signed-ranks test was used for comparing pre- and post-chemotherapy measurements. Results: Mean TBF decreased by 49%. Mean TBF in complete responders (ypT0N0/ypTis) was not significantly different from non-complete responders (≥ypT1) (p = 0.52). Conclusions: Despite a measurable decrease in TBF after chemotherapy treatment, we were not able to estimate a TBF threshold for identifying complete responders to chemotherapy for MIBC patients. Further studies are needed to elucidate the potential of [15O]H2O PET/MRI in assessing therapy response in MIBC. Full article
(This article belongs to the Special Issue Treatment of Bladder Cancer: From Past to Future)
Show Figures

Figure 1

Other

Jump to: Research

14 pages, 655 KiB  
Systematic Review
Choosing between Orthotopic Neobladder and Ileal Conduit after Radical Cystectomy: Tools for Assessing Patient-Specific Characteristics and Enhancing the Decision-Making Process—A Review of Current Studies
by Maciej Trzciniecki, Paweł Kowal, Jan Kołodziej, Tomasz Szydełko and Anna Kołodziej
J. Clin. Med. 2024, 13(12), 3506; https://doi.org/10.3390/jcm13123506 - 15 Jun 2024
Viewed by 1215
Abstract
Objective: The aim of the study was to find tools to assess patient characteristics that would help in choosing between orthotopic neobladder and ileal conduit in patients undergoing radical cystectomy. An additional goal was to search for aids that improve preoperative counseling [...] Read more.
Objective: The aim of the study was to find tools to assess patient characteristics that would help in choosing between orthotopic neobladder and ileal conduit in patients undergoing radical cystectomy. An additional goal was to search for aids that improve preoperative counseling to support patients in the decision-making process. Methods: A systematic review of MEDLINE, Web of Science, and Scopus databases was conducted, according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) statement, in April 2024. Inclusion criteria were specified in PICO format. Two reviewers independently screened titles/abstracts and full papers. Upon study selection, the results and conclusions from the studies were abstracted and quantitatively summarized in the results section of this article. Results: Seven articles, involving a total 834 patients, were included. One article described frailty, two reviewed cognitive status, one article described functional dexterity, one described personality, two articles reviewed patients’ values and goals, and one article reviewed role of patient–physician dialogue in the context of choosing UD after RC. The reviewed articles identified tools and approaches that could be valuable in evaluating the suitability for continent urinary diversion (CUD) or incontinent urinary diversion (ICUD). Conclusions: This is the first systematic review that summarizes the new available methods of patient assessment which improve preoperative counseling and choosing the most suitable UD after RC. Efficient tools for this purpose are still missing, and further studies that will aid in creating a simple aid for patient selection are necessary. Full article
(This article belongs to the Special Issue Treatment of Bladder Cancer: From Past to Future)
Show Figures

Figure 1

Back to TopTop